Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.85 USD | +2.48% | +8.88% | +16.30% |
Financials (USD)
Sales 2024 * | 34.43M | Sales 2025 * | 19.08M | Capitalization | 488M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -108M | EV / Sales 2024 * | 10.4 x |
Net cash position 2024 * | 130M | Net cash position 2025 * | 10.2M | EV / Sales 2025 * | 25 x |
P/E ratio 2024 * |
-5.39
x | P/E ratio 2025 * |
-4.88
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.61% |
Latest transcript on Fulcrum Therapeutics, Inc.
1 day | +2.48% | ||
1 week | +8.88% | ||
1 month | +2.61% | ||
3 months | -28.57% | ||
6 months | +57.31% | ||
Current year | +16.30% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +9.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 7.85 | +2.61% | 365,770 |
24-05-30 | 7.65 | -1.54% | 340,468 |
24-05-29 | 7.77 | +0.39% | 473,581 |
24-05-28 | 7.74 | +7.35% | 1,021,066 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.30% | 488M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- FULC Stock